BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BioMarin Pharma (BMRN) Tops Q1 EPS by 19c, Offers FY Guidance
April 29, 2021 4:13 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.09, $0.19 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $486 million versus the consensus estimate of $446.45 million.
GUIDANCE:
BioMarin Pharma sees FY2021 revenue of $1.75-1.85 billion, versus the consensus of... More
